iiCON bridges the gap in the infection innovation ecosystem between industry, academia, and the NHS, to accelerate and support the discovery and development of innovative new anti-infectives, diagnostics, and preventative products.
iiCON is a world leading centre for infection innovation and R&D – working with industry, academics, and clinicians to save and improve lives around the world by supporting innovation and progressing the development of antimicrobial products and treatments.
Established in 2020, iiCON brings together industry, academia, and the NHS in a concerted effort with a clear aim: to save lives globally by accelerating the discovery and development of new treatments, diagnostics, vaccines, and preventative products for infectious diseases.
Based within the North West of England and led by Liverpool School of Tropical Medicine, iiCON’s partners are Unilever, Liverpool University Hospitals Foundation Trust, University of Liverpool, Evotec, and Infex Therapeutics.
The consortium works with companies of all sizes, supporting them at all stages of the innovation journey, from product concept to adoption.
iiCON does this by enabling impactful collaborations and providing companies with access to world leading expertise and facilities across ten specialist research platforms co-developed and operated by its industrial, academic, and clinical partners.
We partner with companies from early-stage start-ups to global pharma leaders to support
their innovation and fast-track new products and treatments to patients and communities.
iiCON’s commercially sustainable, open-access model provides industry with world-class expertise, facilities, and resources – supporting every stage of the innovation journey from discovery to adoption.
Our early-stage-discovery platforms offer sophisticated expertise & facilities to support world-leading innovation. This knowledge & capability enables the discovery of innovative diagnostics & antimicrobials, bringing forward transformative novel candidates to combat global challenges including multi-drug resistance.
Our Translation platforms support the development of novel antimicrobials & diagnostics. Specialist support is available to progress novel therapeutics from hits to leads. Highly innovative technologies including nanotherapeutics, innovative humanised tissue & microfluidic models, including organoid systems & Organ-on-Chip is accessible to industry to fast-track drug discovery. New drug development pathways are being developed to support the industry effort to combat multi-drug-resistant superbugs.
World-class facilities & expertise support product evaluation & validation. Our expertise in Human Challenge trials offers industry co-located research & clinical facilities, with impactful first-in-human trials run by world-leading researchers available for all antimicrobial applications, significantly de-risking the transition into humans. Our platforms also offer validation & verification of non-invasive diagnostics & advanced surface science capability from leading research institutions.
Our Adoption platforms shape & inform global health policy and support market access, helping to protect communities from diseases including Malaria. Our experts also work closely with industry & policy makers to position health interventions & products to enable maximum public health benefit.